-
Epigenetic heterogeneity hotspots in human liver disease progression Hepatology (IF 12.9) Pub Date : 2024-07-19 Ryan Hlady, Xia Zhao, Louis El Khoury, Ryan Wagner, Aesis Luna, Kien Pham, Nikolaos Pyrosopoulos, Dhanpat Jain, Liguo Wang, Chen Liu, Keith Robertson
■: Disruption of the epigenome is a hallmark of human disease including liver cirrhosis and hepatocellular carcinoma (HCC). While genetic heterogeneity is an established effector of pathologic phenotypes, epigenetic heterogeneity is less well understood. Environmental exposures alter the liver-specific DNA methylation landscape and influence the onset of liver cancer. Given that currently available
-
CX3CR1+ macrophages interact with hepatic stellate cells to promote hepatocellular carcinoma through CD8+ T cell suppression Hepatology (IF 12.9) Pub Date : 2024-07-19 Jong-Min Jeong, Sung Eun Choi, Young-Ri Shim, Hee-Hoon Kim, Young-Sun Lee, Keungmo Yang, Kyurae Kim, Min Jeong Kim, Katherine Po Sin Chung, Seok-Hwan Kim, Jin-Seok Byun, Hyuk Soo Eun, Won-Il Jeong
Background and Aims: Hepatic stellate cells (HSCs) contribute to hepatocellular carcinoma (HCC) progression by regulating multiple factors. However, the entire immunoregulatory functions of HSCs are still obscure. Here, we aim to investigate whether HSCs impose CX3CR1+ macrophages to pro-tumorigenic properties in the peritumoral area. Approach and Results: In single cell RNA-sequencing analysis of
-
Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD Hepatology (IF 12.9) Pub Date : 2024-07-19 Sander Lefere, Antonella Mosca, Christian Hudert, Ellen Dupont, Emer Fitzpatrick, Eirini Kyrana, Anil Dhawan, Laura Kalveram, Andrea Pietrobattista, Anja Geerts, Ruth De Bruyne
Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent pediatric liver disease, yet accurate risk scores for referral of children/adolescents with suspected clinically significant liver fibrosis are currently lacking. Approach & Results: Clinical and biochemical variables were collected in a prospective cohort of 327 children and adolescents with severe
-
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment Hepatology (IF 12.9) Pub Date : 2024-07-19 Ciro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, Salvatore Battaglia, Marco Enea, Bernhard Scheiner, Antonio D’Alessio, Giulia F. Manfredi, Bernardo Stefanini, Naoshi Nishida, Peter R. Galle, Kornelius Schulze, Henning Wege, Roberta Ciccia, Wei-Fan Hsu, Caterina Vivaldi, Brooke Wietharn, Ryan Po-Ting Lin, Angelo Pirozzi, Tiziana Pressiani, Andrea Dalbeni, Leonardo A. Natola, Alessandra
Background&aims: Unlike other malignancies, hepatic functional reserve competes with tumour progression in determining the risk of mortality from hepatocellular carcinoma (HCC). However, the relative contribution of hepatic decompensation over tumour progression in influencing overall survival (OS) has not been assessed in combination immunotherapy recipients. Approach&Results: From the AB-real observational
-
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in Kupffer cells in mice Hepatology (IF 12.9) Pub Date : 2024-07-19 Juanjuan Li, Yinghong Zheng, Zhenzhen Duan, Qingye Zeng, Jin Qu, Jincheng Zhang, Jiao Liu, Wenlong Shang, Xixi Tao, Tingting Yu, Xinzhi Li, Lifu Wang, Liming Yang, Deping Kong, Ying Yu
Background and aims: The liver possesses a remarkable regenerative capacity in response to injuries or viral infections. Various growth factors and cytokines are involved in regulating liver regeneration. Prostaglandin (PG) D2, a pro-resolution lipid mediator, is the most abundant hepatic prostanoid. However, the role of PGD2 in the injury-induced liver regeneration remains unclear. Approach and results:
-
Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content: Systematic review and network meta-analysis Hepatology (IF 12.9) Pub Date : 2024-07-19 Benjamin Koh, Jieling Xiao, Cheng Han Ng, Michelle Law, Shyna Zhuoying Gunalan, Pojsakorn Danpanichkul, Vijay Ramadoss, Benedix Kuan Loon Sim, En Ying Tan, Chong Boon Teo, Benjamin Nah, Margaret Teng, Karn Wijarnpreecha, Yuya Seko, Mei Chin Lim, Hirokazu Takahashi, Atsushi Nakajima, Mazen Noureddin, Mark Muthiah, Daniel Q. Huang, Rohit Loomba
Background and Aims: Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of liver disease. Dynamic changes in magnetic resonance imaging (MRI) proton-density-fat fraction (PDFF) are associated with MASH resolution. We aimed to determine the relative efficacy of therapeutic agents for reducing hepatic fat, assessed by magnetic resonance imaging (MRI) proton-density-fat fraction
-
Drug interaction with Udp-Glucuronosyltransferase (UGT) enzymes is a predictor of drug-induced liver injury Hepatology (IF 12.9) Pub Date : 2024-07-18 AyoOluwa O. Olubamiwa, Tsung-Jen Liao, Jinwen Zhao, Patrice Dehanne, Catherine Noban, Yeliz Angin, Olivier Barberan, Minjun Chen
DILI frequently contributes to the attrition of new drug candidates and is a common cause for the withdrawal of approved drugs from the market. Although some noncytochrome P450 (non-CYP) metabolism enzymes have been implicated in DILI development, their association with DILI outcomes has not been systematically evaluated. In this study, we analyzed a large data set comprising 317 drugs and their interactions
-
Letter to the Editor: Authors reply to “accurate predictor for liver disease progression in patients with DC/TBD” Hepatology (IF 12.9) Pub Date : 2024-07-18 Neelan Giri, Marena R. Niewisch, Philip S. Rosenberg, Anusha Vittal, Sharon A. Savage, Theo Heller
-
Alcohol-associated liver disease: The time to act is now Hepatology (IF 12.9) Pub Date : 2024-07-17 Harmeet Malhi, Gregory J. Gores
-
Accurate predictor for liver disease progression in patients with DC/TBD Hepatology (IF 12.9) Pub Date : 2024-07-17 Jing Zhao, Yue Bi
-
-
Letter to the Editor: Exercise greater caution in bile acid research Hepatology (IF 12.9) Pub Date : 2024-07-17 Chenhe Yi, Lirong Chen, Baorui Tao, Xiangyu Wang, Jin Lin, Jinhong Chen
-
Reply to: Exercise greater caution in bile acid research Hepatology (IF 12.9) Pub Date : 2024-07-17 Yuan Zhuang, Marti Ortega-Ribera, Gyongyi Szabo
-
Letter to the Editor: The causal analysis of missing confounding-factors for the association between HDV with specific liver events Hepatology (IF 12.9) Pub Date : 2024-07-17 Zheng Li, Yi Zhang, Ying Li, Jie Lan, Yuzhu Hu, Qianqian Meng, Laraib Nadeem, Bingwen Zou
-
S-pecial Delivery: Implications of HBV Surface Antigen Subviral particles Carrying microRNA Payloads Hepatology (IF 12.9) Pub Date : 2024-07-17 Adam J Gehring
-
Reply: The causal analysis of missing confounding-factors for the association between HDV with specific liver events Hepatology (IF 12.9) Pub Date : 2024-07-17 Robert G. Gish, Robert J. Wong, Gian Luca Di Tanna, Ankita Kaushik, Chong Kim, Nathaniel J. Smith, Patrick TF Kennedy
-
-
An integrated analysis of bile acid metabolism in humans with severe obesity Hepatology (IF 12.9) Pub Date : 2024-07-16 Ömrüm Aydin, Annika Wahlström, Patrick A. de Jonge, Abraham S. Meijnikman, Wilhelm Sjöland, Lisa Olsson, Marcus Henricsson, Marcus C. de Goffau, Stijn Oonk, Sjoerd C. Bruin, Yair I.Z. Acherman, Hanns-Ulrich Marschall, Victor E.A. Gerdes, Max Nieuwdorp, Fredrik Bäckhed, Albert K. Groen
Background and Aims: Bile acids (BA) are vital regulators of metabolism. BAs are AQ6 secreted in the small intestine, reabsorbed, and transported back to the liver, where they can modulate metabolic functions. There is a paucity of data regarding the portal BA composition in humans. This study aimed to address this knowledge gap by investigating portal BA composition and the relation with peripheral
-
Developing Quality Measures for Improving Pre-Liver Transplant Care Hepatology (IF 12.9) Pub Date : 2024-07-16
-
Hepatic IL22RA1 deficiency promotes hepatic steatosis by modulating oxysterol in the liver Hepatology (IF 12.9) Pub Date : 2024-07-10 Yeping Huang, Fan Yu, Yue Ding, Hong Zhang, Xinyue Li, Xiao Wang, Xiaoshan Wu, Jie Xu, Liang Wang, Chenxu Tian, Min Jiang, Rong Zhang, Chenyan Yan, Yingxiang Song, Haijun Huang, Guangzhong Xu, Qiurong Ding, Xiao Ye, Yan Lu, Cheng Hu
Background & Aims: Imbalance in lipid metabolism is the main cause of nonalcoholic fatty liver disease (NAFLD). While the pathogenesis of lipid accumulation mediated by extrahepatic regulators has been extensively studied, the intrahepatic regulators modulating lipid homeostasis remain unclear. Previous studies have shown that systemic administration of interleukin-22 (IL-22) protects against NAFLD;
-
Intestinal IL-33 promotes microbiota-derived trimethylamine N-oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1α Hepatology (IF 12.9) Pub Date : 2024-07-10 Suping Hai, Xitang Li, Erliang Xie, Wenhui Wu, Qiang Gao, Binghui Yu, Junjian Hu, Feiyang Xu, Xizhe Zheng, Bin-hao Zhang, Di Wu, Weiming Yan, Qin Ning, Xiaojing Wang
Background and Aims: Gut microbiota play a prominent role in the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD). Interleukin-33 (IL-33) is highly expressed at mucosal barrier sites and regulates intestinal homeostasis. Herein, we aimed to investigate the role and mechanism of intestinal IL-33 in MASLD. Approach and Results: In both human and mice with MASLD, hepatic
-
Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation Hepatology (IF 12.9) Pub Date : 2024-07-10 Liangjun Zhang, Pingfan Xie, Mingqiao Li, Xiaoxun Zhang, Shuke Fei, Nan Zhao, Ling Li, Qiaoling Xie, Ziqian Xu, Wan Tang, Guanyu Zhu, Zhixian Zhu, Zuzhi Xu, Jianwei Li, Chengcheng Zhang, James L. Boyer, Wensheng Chen, Shi-Ying Cai, Qiong Pan, Jin Chai
Background and Aims: Inflammatory response is crucial for bile acid (BA)-induced cholestatic liver injury, but molecular mechanisms remain to be elucidated. Solute Carrier Family 35 Member C1 (SLC35C1) can transport GDP-fucose into the Golgi to facilitate protein glycosylation. Its mutation leads to the deficiency of leukocyte adhesion and enhances inflammation in humans. However, little is known about
-
Letter to the Editor: Utilization of beta blockers in patients with portal hypertension and peripheral artery disease Hepatology (IF 12.9) Pub Date : 2024-07-10 Jon M. Hoover
-
SLC10A5 deficiency causes hypercholanemia Hepatology (IF 12.9) Pub Date : 2024-07-10 Yuqing Xu, Yeqing Qian, Ying Yu, Xin Zhan, Pengzhen Jin, Jiawei Hong, Minyue Dong
Background and Aims: Solute Carrier Family 10 Member 5 (SLC10A5) is a member of SLC10, comprising transporters of bile acids, steroidal hormones and other substrates, but its function remains unclear. The aim of the current investigation was to clarify its function in the metabolism of bile acid and hypercholanemia. Approach: Whole-exome sequencing and Sanger sequencing were used to identify and confirm
-
Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure Hepatology (IF 12.9) Pub Date : 2024-07-08 Georg Semmler, Sonia Alonso López, Monica Pons, Sabela Lens, Elton Dajti, Marie Griemsmann, Alberto Zanetto, Lukas Burghart, Stefanie Hametner-Schreil, Lukas Hartl, Marisa Manzano, Sergio Rodriguez-Tajes, Paola Zanaga, Michael Schwarz, María Luisa Gutierrez, Mathias Jachs, Anna Pocurull, Benjamín Polo, Dominik Ecker, Beatriz Mateos, Sonia Izquierdo, Yolanda Real, Lorenz Balcar, Juan Antonio Carbonell-Asins
Background & Rationale: Around 750.000 patients/year will be cured from hepatitis C-virus (HCV)-infection until 2030. Those with compensated advanced chronic liver disease (cACLD) remain at risk for hepatic decompensation and de-novo hepatocellular carcinoma (HCC). Algorithms have been developed to stratify risk early after cure, however, data on long-term outcome and the prognostic utility of these
-
A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally-suppressed, HBeAg negative chronic hepatitis B patients Hepatology (IF 12.9) Pub Date : 2024-07-08 Jiandan Qian, Yao Xie, Qianguo Mao, Qing Xie, Ye Gu, Xinyue Chen, Guoxin Hu, Yongfeng Yang, Jiajie Lu, Guizhou Zou, Qin Zhang, Lei Fu, Yongping Chen, Xiaolin Guo, Jinlin Hou, Yuemei Yan, Jinzi J. Wu, Yimin Cui, Guiqiang Wang
Background & Aims: Studies have shown that blocking the PD-1/PD-L1 pathway may lead to a potential cure for HBV infections. ASC22 (Envafolimab) is a humanized, single-domain PD-L1 antibody administered subcutaneously. This study aimed to evaluate the efficacy and safety of ASC22 in virally suppressed chronic hepatitis B (CHB) patients on nucleos(t)ide analogs (NAs). Approach and Results: This randomized
-
Tumor suppressive role of the antimicrobial lectin REG3A targeting the O-GlcNAc glycosylation pathway Hepatology (IF 12.9) Pub Date : 2024-07-08 Nicolas Moniaux, Nicolas Geoffre, Marion Darnaud, Alice Deshayes, Alexandre Dos Santos, Sylvie Job, Claire Lacoste, Tung-Son Nguyen, Mélanie Friedel-Arboleas, Catherine Guettier, Janne Purhonen, Jukka Kallijärvi, Gilles Amouyal, Paul Amouyal, Christian Bréchot, Romain Vives, Marie Annick Buendia, Tarik Issad, Jamila Faivre
Background and Aims: Antimicrobial proteins of the REG3 family provide a first line of protection against infections and transformed cells. Their expression is inducible by inflammation, which makes their role in cancer biology less clear, since an immune- inflammatory context may preexist or coexist with cancer, as occurs in hepatocellular carcinoma (HCC). The aim of this study is to clarify the role
-
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors Hepatology (IF 12.9) Pub Date : 2024-07-02 Deniz Kent, Soon Seng Ng, Adam M. Syanda, Payam Khoshkenar, Riccardo Ronzoni, Chao Zheng Li, Marina Zieger, Cindy Greer, Stephanie Hatch, Joe Segal, Samuel JI Blackford, Yu Ri Im, Vivek Chowdary, Taylor Ismali, Davide Danovi, Patrick A. Lewis, James A. Irving, Sunil Sahdeo, David A. Lomas, Daniel Ebner, Christian Mueller, S. Tamir Rashid
Alpha-1 antitrypsin deficiency (A1ATD) is a life-threatening condition caused by inheritance of the SERPINA1 ‘Z’ genetic variant (PiZ) driving AAT protein misfolding in hepatocytes. There remain no approved medicines for this disease. Here, we report the results of a small molecule screen performed in patient derived iPSC-hepatocytes that identified Leucine-rich repeat kinase-2 (LRRK2) as a potentially
-
Role of Point-of-Care ultrasound (POCUS) in clinical hepatology Hepatology (IF 12.9) Pub Date : 2024-07-02 Madhumita Premkumar, Constantine J. Karvellas, Anand V. Kulkarni, Harish Bhujade, K. Rajender Reddy
Hospitalized patients with cirrhosis frequently require critical care management for sepsis, hepatic encephalopathy, respiratory failure, acute variceal bleeding, acute kidney injury (AKI), shock and optimization for liver transplantation (LT), while outpatients have unique care considerations. Point-of-care ultrasonography (POCUS) enhances bedside examination of the hepatobiliary system and relevant
-
Alcohol-associated liver disease and public health policies Hepatology (IF 12.9) Pub Date : 2024-07-01 Shreya Sengupta, Victoria Gill, Jessica L. Mellinger
Alcohol-associated liver disease (ALD) rates have increased substantially in the United States (US) and elsewhere around the globe. These increases are largely the result of increases in alcohol use. While there are many levels at which alcohol use interventions can be implemented in order to reduce alcohol use and its negative health consequences, public policy initiatives have emerged as a powerful
-
To recover or not to recover from ACLF: Ask the monocytes Hepatology (IF 12.9) Pub Date : 2024-07-01 Amin M. Amin, Jacqueline G. O’Leary
-
A novel phosphodiesterase inhibitor for the treatment of chronic liver injury and metabolic diseases Hepatology (IF 12.9) Pub Date : 2024-07-01 Dalton W. Staller, Sanjali S. Panigrahi, Yahani P. Jayasinghe, Yuxiang Dong, Sohan Mahto, Virender Kumar, Donald R. Ronning, Ram I. Mahato
Background and Aims: Chronic liver disease (CLD) leads to approximately two million deaths annually. Cyclic adenosine monophosphate (cAMP) signaling has long been studied in liver injury, particularly in the regulation of fatty acid (FA) β-oxidation and pro-inflammatory polarization of tissue-resident lymphocytes. Phosphodiesterase 4B (PDE4B) inhibition has been explored as a therapeutic modality,
-
Is curcumin the new kid on the block for the treatment of MASH? Hepatology (IF 12.9) Pub Date : 2024-06-28 Shira Zelber-Sagi, Jörn M. Schattenberg
-
Reversal of lipid metabolism as a therapeutic approach for hepatocellular carcinoma Hepatology (IF 12.9) Pub Date : 2024-06-27 Daming Gao, Judy Wai Ping Yam
-
Letter to the Editor: Refining retrieval and chunking strategies for enhanced clinical reliability of large language models in liver disease Hepatology (IF 12.9) Pub Date : 2024-06-27 Mauro Giuffrè
-
Reply: Refining retrieval and chunking strategies for enhanced clinical reliability of large language models in liver disease Hepatology (IF 12.9) Pub Date : 2024-06-27 Jin Ge, Steve Sun, Joseph Owens, Victor Galvez, Oksana Gologorskaya, Jennifer C. Lai, Mark J. Pletcher, Ki Lai
-
Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder Hepatology (IF 12.9) Pub Date : 2024-06-27 Lamia Y. Haque, Lorenzo Leggio
The public health impact of alcohol-associated liver disease (ALD), a serious consequence of problematic alcohol use, and alcohol use disorder (AUD) is growing, with ALD becoming a major cause of alcohol-related death overall and the leading indication for liver transplantation in the United States. Comprehensive care for ALD often requires treatment of AUD. Although there is a growing body of evidence
-
Bridging the gap: A new tool to down select HCV vaccine candidates Hepatology (IF 12.9) Pub Date : 2024-06-27 John Lokman Law, Heidi E. Drummer
-
Alcohol-Associated liver disease: Emerging therapeutic strategies Hepatology (IF 12.9) Pub Date : 2024-06-26 Benjamin H. Mullish, Mark R. Thursz
The large and growing burden of alcohol-related liver disease (ALD) – and the considerable burden of morbidity and mortality associated with it – has been a drive towards ongoing research into novel strategies for its treatment, with a particular focus upon alcohol-related hepatitis (AH). Management of alcohol-use disorder (AUD) forms the central pillar of ALD care, with evidence-based psychological
-
Letter to the Editor: Chronic hepatitis B baseline viral load and on-treatment liver cancer risk: A multinational cohort study of HBeAg-positive patients Hepatology (IF 12.9) Pub Date : 2024-06-26 Xingmei Liao, Rong Fan
-
Therapeutic manipulation of the microbiome in liver disease Hepatology (IF 12.9) Pub Date : 2024-06-26 Gopanandan Parthasarathy, Harmeet Malhi, Jasmohan S. Bajaj
Myriad associations between the microbiome and various facets of liver physiology and pathology have been described in the literature. Building on descriptive and correlative sequencing studies, metagenomic studies are expanding our collective understanding of the functional and mechanistic role of the microbiome as mediators of the gut-liver axis. Based on these mechanisms, the functional activity
-
‘Regarding Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography’ Hepatology (IF 12.9) Pub Date : 2024-06-26 Madhumita Premkumar, Anand Kulkarni, Manhal Izzy
-
Aramchol improves hepatic fibrosis in MASH: Results of multimodality assessment using both conventional and digital pathology Hepatology (IF 12.9) Pub Date : 2024-06-25 Vlad Ratziu, Yusuf Yilmaz, Don Lazas, Scott L. Friedman, Caroline Lackner, Cynthia Behling, Oscar W. Cummings, Li Chen, Matthieu Petitjean, Yossi Gilgun-Sherki, Tali Gorfine, Shaul Kadosh, Eli Eyal, Arun J. Sanyal
Background and Aims: Antifibrotic trials rely on conventional pathology (CP) despite recognized limitations. We compared single fiber digital image analysis (DIA) with CP to quantify the antifibrotic effect of Aramchol, a stearoyl-CoA desaturase 1 inhibitor in development for metabolic-dysfunction associated steatohepatitis (MASH). Approach and Results: 51 MASH patients enrolled in the open-label part
-
Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury Hepatology (IF 12.9) Pub Date : 2024-06-25 Xin Luo, Jixian Yu
-
Letter to the Editor: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis Hepatology (IF 12.9) Pub Date : 2024-06-24 Kai Kang, Yijun Wu
-
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study Hepatology (IF 12.9) Pub Date : 2024-06-24 Meng Zhu, Mengqi Qu, Shengxia Lv, Fuzhen Pan, Yongsheng Zhang
-
Letter to the Editor: Imaging-based noninvasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline Hepatology (IF 12.9) Pub Date : 2024-06-24 Fei Zhang, Jiahe Wang
-
Modulation of monocyte activity by hepatocellular MicroRNA delivery via hepatitis B virus surface antigen particles: Implications for pathobiology of chronic hepatitis B Hepatology (IF 12.9) Pub Date : 2024-06-21 Jin Li, Xiao Ma, Qinkao Xuan, Qiang Li, Min Wu, Bisheng Shi, Zhong Fang, Liang Chen, Jieliang Chen, Yumei Wen, Chuanwu Zhu, Li Zhu, Xiaonan Zhang, Zhenghong Yuan
Background and Aims: The surface antigen of hepatitis B virus (HBsAg) serves as an important immune-modulatory factor in chronic hepatitis B (CHB). One aspect of such modulation may act through monocytes which are the major antigen presenting cells (APCs) taking up HBsAg. There is evidence for the encapsulation of hepatocellular miRNAs by HBsAg particles, while its pathobiological significance is unclear
-
Utility of methylated DNA markers for the diagnosis of malignant biliary strictures Hepatology (IF 12.9) Pub Date : 2024-06-21 Matthew A. Cooley, Amber R. Schneider, Emily G. Barr Fritcher, Dragana Milosevic, Michael J. Levy, Amber R. Bridgeman, John A. Martin, Bret T. Petersen, Barham K. Abu Dayyeh, Andrew C. Storm, Ryan J. Law, Eric J. Vargas, Vishal Garimella, Tyler Zemla, Sarah M. Jenkins, Jun Yin, Gregory J. Gores, Lewis R. Roberts, Benjamin R. Kipp, Vinay Chandrasekhara
Background and Aims: Early identification of malignant biliary strictures (MBS) is challenging, with up to 20% classified as indeterminants after preliminary testing and tissue sampling with endoscopic retrograde cholangiopancreatography (ERCP). We aimed to evaluate the use of methylated DNA markers (MDM) from biliary brushings to enhance MBS detection in a prospective cohort. Methods: Candidate MDMs
-
Letter to the Editor: MAFLD versus MASLD criteria debate- Certainly not for children! Hepatology (IF 12.9) Pub Date : 2024-06-20 Mortada H. F. El-Shabrawi, Abdelaziz Elamin, Naglaa M. Kamal
-
Spatial proteomic landscape of primary and relapsed hepatocellular carcinoma reveals immune escape characteristics in early relapse Hepatology (IF 12.9) Pub Date : 2024-06-20 Meilin Yang, Xiaoyi Song, Fan Zhang, Mingan Li, Wuguang Chang, Zheyan Wang, Man Li, Hong Shan, Dan Li
Background & Aims: Surgical resection serves as the principal curative strategy for hepatocellular carcinoma (HCC), yet the incidence of postoperative recurrence remains alarmingly high. However, the spatial molecular structural alterations contributing to postoperative recurrence in HCC are still poorly understood. Approach & Results: We employed imaging mass cytometry to profile the in-situ expression
-
Reply: Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis Hepatology (IF 12.9) Pub Date : 2024-06-20 Juan Berenguer, José M. Bellón, Rafael Bañares, Juan González-García
-
Genetic predisposition to porto-sinusoidal vascular disorder Hepatology (IF 12.9) Pub Date : 2024-06-20 Nadia Ciriaci, Lise Bertin, Pierre-Emmanuel Rautou
Porto-sinusoidal vascular disorder is a rare liver disease. The pathophysiological mechanisms underlying the development of porto-sinusoidal vascular disorder are unknown. Isolated cases of porto-sinusoidal vascular disorder associated with gene mutations have been reported, but no overview is available. Therefore, we performed an extensive literature search to provide a comprehensive overview of gene
-
Real-world evidence for factors associated with maintenance treatment practices among U.S. adults with autoimmune hepatitis Hepatology (IF 12.9) Pub Date : 2024-06-12 Therese Bittermann, Lina Yagan, Ranganath G. Kathawate, Ethan M. Weinberg, Eliot G. Peyster, James D. Lewis, Cynthia Levy, David S. Goldberg
Background & Aims: While avoidance of long-term corticosteroids is a common objective in the management of autoimmune hepatitis (AIH), prolonged immunosuppression is usually required to prevent disease progression. This study investigates the patient and provider factors associated with treatment patterns in U.S. patients with AIH. Approach & Results: A retrospective cohort of adults with incident
-
Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases Hepatology (IF 12.9) Pub Date : 2024-06-11 Shouzhi Yang, Jing Fu, Wenhao Qin, Ruimin Wang, Mingye Gu, Yida Huang, Wanshan Liu, Haiyang Su, Xiaoyu Xu, Wei Chen, Ayizekeranmu Yiming, Bing Hu, Lin Huang, Kun Qian, Hongyang Wang
Background and Aims: Biliary tract cancers (BTCs) are aggressive gastrointestinal malignancies characterized by a dismal 5-year overall survival rate less than 20%. Current diagnostic modalities suffer from limitations regarding sensitivity and specificity. This study aimed to develop a bile metabolite-based platform for precise discrimination between malignant and benign biliary diseases. Approach
-
REPLY: The exact predictive value of HBcrAg and HBV RNA in serological status and disease activity in CHB Hepatology (IF 12.9) Pub Date : 2024-06-11 Marc G. Ghany, Wendy C. King, Amanda S. Hinerman, Anna S.F. Lok, Mauricio Lisker-Melman, Raymond T. Chung, Norah Terrault, Harry L.A. Janssen, Mandana Khalili, William M. Lee, Daryl T.Y. Lau, Gavin A. Cloherty, Richard K. Sterling
-
Baseline viral load in chronic hepatitis B may be clinically significant but must be interpreted with caution Hepatology (IF 12.9) Pub Date : 2024-06-06 Tong Tang, Li-Qin Li, Zhao-Di Wang
-
Reply: Imaging-based non-invasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline Hepatology (IF 12.9) Pub Date : 2024-06-05 Andres Duarte-Rojo, Bachir Taouli, Daniel H. Leung, Deborah Levine, Tarek Nayfeh, Bashar Hasan, Yahya Alsawaf, Samer Saadi, Abdul Mounaem Majzoub, Apostolos Manolopoulos, Samir Haffar, Ayca Dundar, M. Hassan Murad, Don C. Rockey, Mouaz Alsawas, Richard K. Sterling
-
Early treatment of acute or recently acquired hepatitis C - an important tool on the path to HCV elimination! Hepatology (IF 12.9) Pub Date : 2024-06-05 Markus Cornberg, Heiner Wedemeyer
-
Letter to the Editor: New confounders emerging with new evidence regarding reduced HCC and improved survival Hepatology (IF 12.9) Pub Date : 2024-06-05 Yue Hu, Zheng Li, Qiang Li, Xiaodong Jin, Cuixia Di, Weilan He, Xinran Cheng